Kornimate/medical-research-clean huggingface dataset:
premature coronary artery disease (cad) in severe psoriasis

Conditions: Psoriasis; Coronary Artery Disease

Summary: the purpose of this study is to compare the prevalence and severity of cad (coronary artery disease) in patients with and without severe psoriasis, otherwise matched for cardiovascular risk factors.

to establish the relationship between psoriasis and coronary disease by comparing the prevalence and severity of cad (coronary artery disease) in patients with and without severe psoriasis, otherwise matched for cardiovascular risk factors, as determined by ct coronary calcium scoring and coronary ct angiography.

Eligibility criteria:
inclusion criteria: 1. patients with severe psoriasis as determined by more than two episodes of systemic or inpatient treatment and 10% or more body surface area involvement. 2. male or female ages 18 to 55 (because cad risk has been shown to be greatest in younger psoriasis patients in earlier studies, this pilot study will focus on young individuals). 3. able to give informed consent exclusion criteria: 1. prior diagnosis of cad (coronary artery disease) or heart disease based upon one or more of the following: * coronary arteriography * percutaneous coronary intervention * cardiac surgery including bypass graft surgery * valve surgery * congenital heart disease repair * stress ecg or imaging * myocardial infarction * angina or unstable angina * congestive heart failure * cardiomyopathy 2. history of anti-oxidants such as fish oil or biologic therapy tumor necrosis factor alpha inhibitors (such as etanercept, adalimumab, or infliximab). a recent review by sattar et al \[22\] has shown preliminary evidence that tnf (tumor necrosis factor) blockade can modulate nontraditional cardiovascular risk factors such as c-reactive protein(crp), interleukin-6(il-6), apolipoprotein ai(apoai), lipoprotein(a)(lp\[a\]), sex hormone binding globulin (shbg), and homocysteine to exert a possible vascular and metabolic protective effect. 3. pustular and erythrogenic psoriasis 4. unable to give informed consent 5. contraindications to coronary ct, including: * irregular heart rate, such as multiple pvcs (premature ventricular contractions), atrial fibrillation * active heart failure * serum creatinine \> 1.5mg/dl * weight \> 320 lbs (due to degradation in ct (computerized tomography)image quality by image noise) * history of severe allergy to intravenous contrast media * high irregular heart rate with contraindications to beta-blockers * pregnant

Keywords: psoriasis coronary arteriosclerosis coronary events rheumatoid arthritis arthritis
study of surgical treatment versus observation in children with moderate intermittent exotropia

Conditions: Moderate Intermittent Exotropia

Summary: the purpose of this study is to determine the long-term effect and security of the surgical treatment and observation only on ocular alignment, binocular stereopsis, and quality of life in children with moderate intermittent exotropia.


Eligibility criteria:
inclusion criteria: 1. to correspond the definition of ixt: monocular or binocular alternative exotropia, exodeviation at distance for 15 prism diopters at least, can control the normal ocular alignment, normal ocular movements. 2. simultaneous perception and fusion point in synoptophore, but no normal function of fusion and stereopsis. 3. age at from 5 to 18 years, sex unlimited. 4. no treatment for ixt previously (including surgical and non-surgical treatment). 5. no amblyopia. 6. signed informed consent form voluntarily. exclusion criteria: 1. accompanied with ocular organic diseases. 2. accompanied with systemic diseases (e.g. nervous system disease). 3. unable to regular follow-up (e.g. from countryside and outlying district). 4. investigators concluded that should be excluded.

Keywords: moderate intermittent exotropia surgical treatment observation
temporomandibular joint in patients with rheumatoid arthritis

Conditions: Temporomandibular Joint Disorders; Rheumatoid Arthritis

Summary: the investigators study aimed to evaluate temporomandibular joint involvement in rheumatoid arthritis patients and healthy individuals 142 participants were recruited in two groups: 72 patients with rheumatoid arthritis (ra), and 70 healthy controls. all participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies. tmd diagnosis was determined according to the standardized and validated diagnostic criteria for tmd (dc/tmd): myalgia, arthralgia, articular disc, displacement, degenerative joint disease, and headache attributed to tmd. bruxism, a probable sleep and/or awake bruxism diagnosis was determined based on self-report and several clinical findings.


Eligibility criteria:
* inclusion criteria included: * age \> 18 years old * individuals who had a minimum of 12 natural teeth. * exclusion criteria * included: trauma or surgery on the jaw * facial nerve paralysis * tooth implant * scleroderma * cerebrovascular accident * schizophrenia * steroid injection within the last six months.

Keywords: rheumatoid arthritis temporomandibular joints bruxism
clopidogrel versus aspirin monotherapy after 1- to 3-month of dual-antiplatelet therapy following zotarolimus-eluting onyx stents implantation; c-mode trial

Conditions: Ischemic Heart Disease

Summary: previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (dapt) after percutaneous coronary intervention (pci), however, the single antiplatelet agent to be maintained after short-term dapt was different. therefore, which antiplatelet agent to be maintained after short-term dapt needs further invstigations.

the investigators hypothesized that short-term (1-3 months) dapt followed by clopidogrel monotherapy will be superior to short-term dapt followed by aspirin monotherapy after pci in patients with ischemic heart disease. we will evaluate whether clopidogrel monotherapy will reduce the rate of net adverse clinical events (nace) at 12 months compared to aspirin monotherapy after very-short term dapt. eligible patients will be randomized to short-term dapt followed by clopidogrel monotherapy or short-term dapt followed by aspirin monotherapy at hospitalization for index pci. randomization will be stratified according to 1) bleeding risk (high bleeding risk \[hbr\] or non-hbr), 2) clinical presentation (acute coronary syndrome or chronic coronary artery disease), and 3) lesion complexity (non-complex or complex lesion). regarding the duration of very-short term dapt, the maintenance duration of dapt (1-month or 3-month) will be determined as follows: * if the patients are at hbr (hbr is defined according to arc-hbr criteria: meeting at least 1 major or 2 minor criteria), 1-month dapt will be given regardless of clinical presentation or lesion complexity. * in the patients are at non-hbr, 3-month dapt will be given in those treated for unstable angina and/or complex lesions (complex lesion is defined as meeting at least one of the following: number of stents implanted ≥3, number of lesions treated ≥3, 3-vessel treated, bifurcation pci with 2 stents, total stent length ≥60mm, or chronic total occlusion).

Eligibility criteria:
inclusion criteria: 1. patients ≥19 years 2. patients who received new generation zotarolimus-eluting onyx stents implantation for treating ischemic heart disease 3. provision of informed consent exclusion criteria: 1. age ≥ 85 years 2. acute myocardial infarction 2. left main bifurcation requiring 2-stent technique 3. pregnant women or women with potential childbearing 4. life expectancy \< 1 year 5. inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator 6. inability to understand or read the informed consent
significance and outcome of magnetic resonance enterography revealing sacroiliitis in crohn's disease: a pilot study

Conditions: Sacroiliitis

Summary: this study aims to further define and characterize imaging findings of possible sacroiliitis in crohn's disease patients by recalling subjects who had findings of possible sacroiliitis on prior mre and assess the natural history and outcome of these cases by using standard magnetic resonance imaging (mri) and x-ray of the sacroiliac joints.

when axial spondyloarthritis (spa) occurs in crohn's disease (cd) is an important clinical and research question that has not been fully answered. magnetic resonance enterography (mre), routinely obtained in crohn's disease (cd) patients, can be utilized to assess sacroiliac joints (sij); currently published literature shows that it could be a valuable tool to detect active inflammation of sacroiliitis in cd patients. only a small fraction of cd patients with mre evidence of sacroiliitis is referred to rheumatologists for further evaluation. the proposed project aims to further define mre features of sacroiliitis in cd by recalling subjects who had prior positive findings and assess the natural history and outcome of these cases by standard magnetic resonance imaging (mri) of sacroiliac joints and sij x-ray. 37 cd subjects who were already found to have sacroiliitis in the previous mre study will be recalled. subjects will undergo standard mri of sij, plain x-ray of sij and the rheumatologist will obtain detailed history and examine patients for evaluation of possible axial spa. other details pertaining to cd, cd therapy and activity, will also be obtained to help clarify a correlation between cd and axial spa. this pilot study will allow better characterization of imaging features of sacroiliitis on mre, provide useful information on clinical significance of these lesions in cd patients, and potentially establish mre as a screening tool for early detection of sacroiliitis in cd patients.

Eligibility criteria:
inclusion criteria: * evidence of sacroiliitis on earlier standard of care mre between 2014 and 2018. * confirmed diagnosis of crohn's disease * known hla-b27 status at time of enrollment and most recent clinical esr and crp results from chart (from day of visit or within past 4 weeks of study visit) * adults \>18 years of age exclusion criteria: * history of other inflammatory arthritis (e.g. rheumatoid arthritis, systemic lupus erythematosus, gout). * contraindication to mri. * history of malignancy \<5 years in remission, (except for non-melanomatous skin cancer). * inability to comply with study protocol. * critically ill patients. * pregnant patients. * non-english speaking patients (as the questionnaires used in this study are not validated in other languages)
study comparing dual combination of product (budesonide and formoterol) given via two different inhalers. to see which one results in the best effect on breathing.

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: study comparing the same drugs as a dual combination product (budesonide and formoterol) given via two different inhalers. to see which one results in the best effect on breathing.

this is a randomized, open-label, two period crossover, chronic dosing, 1-week, pilot study to assess the efficacy and safety of budesonide and formoterol fumarate inhalation aerosol administered with a spacer compared with symbicort® turbuhaler® in subjects with severe to very severe chronic obstructive pulmonary disease and low peak inspiratory flow to assess lung function

Eligibility criteria:
key inclusion criteria: 1. subject must be 40 to 80 years of age inclusive, at the time of signing the icf. 2. individuals who have a physician diagnosis of copd as defined by the american thoracic society (ats)/european respiratory society (ers) 3. require copd maintenance therapy: all subjects must be receiving 2 or more inhaled maintenance therapies, including at least 1 long-acting bronchodilator, for the management of their copd for at least 4 weeks prior to visit 1. 4. a post-bronchodilator fev1/fvc of \<0.70 and post-bronchodilator fev1 of \<50% predicted normal value at visit 2. 5. a pre-bronchodilator pif of \<50 l/min using the incheck inspiratory flow measurement device set to turbuhaler s resistance at visit 2. 6. current or former smokers with history of at least 10 pack-years of cigarette smoking. key exclusion criteria: 1. current diagnosis of asthma, in the opinion of the investigator. 2. other respiratory disorders including known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis (high resolution ct evidence of bronchiectasis that causes repeated acute exacerbations), immune deficiency disorders, severe neurological disorders affecting control of the upper airway, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or pulmonary thromboembolic disease. 3. a moderate or severe exacerbation of copd ending within 6 weeks prior to randomization (visit 3). 4. need for mechanical ventilation within 3 months prior to visit 1.

Keywords: copd
a study of tqb2450 injection combined with stereotactic body radiation therapy (sbrt) in subjects with advanced oligometastatic non-small cell lung cancer

Conditions: Advanced Oligometastatic Non-small Cell Lung Cancer

Summary: tqb2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (pd-l1), which prevents pd-l1 from binding to pd-1 and b7.1 receptors on t cell surface, restores t cell activity, thus enhancing immune response and has potential to treat various types of tumors.


Eligibility criteria:
inclusion criteria: * 1. eastern cooperative oncology group (ecog) performance status score of 0 to 2; life expectancy ≥ 3 months. 2. histologically or pathologically confirmed advanced non-small cell lung cancer. 3. primary lesion controlled oligometastatic patients, the number of metastatic lesions ≤ 5, and has at least one measurable lesion. 4. has received standard first-line chemotherapy, intolerable or inappropriate to the chemotherapy. 5. adequate organ system function. 6. male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；no pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration. 7.understood and signed an informed consent form. exclusion criteria: * 1. has used against pd-1, pd-l1 and other related immunotherapeutic drugs. 2.has mutations in (epidermal growth factor receptor)egfr, (anaplastic lymphoma kinase)alk, (c-ros oncogene 1 receptor kinase)ros1 or t790m and not resistant to targeted drug. 3. has severe hypersensitivity reaction to other monoclonal antibodies. 4. has diagnosed and/or treated additional malignancy within 5 years prior to the first administration.exceptions include cured basal cell carcinoma of skin and carcinoma in situ of cervix. 5. has any active autoimmune disease or a history of autoimmune disease. 6. immunosuppressive therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage \> 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first administration. 7. (magnetic resonance imaging)mri examination found meningeal metastases and cannot be controlled by stereotactic radiotherapy. 8. has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1. 9. has any severe and/or uncontrolled disease. 10. has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first administration. 11. according to the judgement of the researchers, there are other factors that may lead to the termination of the study.
living well with lymphoma

Conditions: Lymphoma

Summary: in this study the investigators are proposing to evaluate the efficacy, sustainability, and mechanisms of 3 months of individualized counseling of the frd delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the frd) the general health curriculum (ghc). the investigators will randomize and follow 68 lymphoma cancer survivors; accounting for a \~10% drop out rate to achieve a target of 60 patients that will complete the study. the investigators hypothesize that persistently fatigued lymphoma cancer survivors will experience improvements in fatigue, quality of life, and symptoms commonly associated with fatigue, which are then maintained at 15-months post-enrollment; and decreased crp and alterations in inflammation-associated dna methylation consistent with reduced inflammation from following the frd as compared to the ghc.


Eligibility criteria:
inclusion criteria: * women and men aged 18 years and older * diagnosis of lymphoma (hodgkin and non-hodgkin) * have an average persistent fatigue defined as ≥ 4 on the brief fatigue inventory * fatigue must be attributed to lymphoma diagnosis * fatigue onset must be between 12months before diagnosis and any time after diagnosis * fatigue must not be attributed to other disease diagnoses * fruit and vegetable intake ≤5.5 servings/day * have, or be willing to create, an email address to receive study questionnaires electronically. exclusion criteria: * medically unstable * bmi\<18.5 kg/m2 * have a current untreated diagnosis of mood disorder, e.g., bipolar or major depressive disorder * have a current untreated diagnosis of anemia * have a current untreated diagnosis of hypothyroidism * have an initiation, a cessation or change of treatment of any chronic medications, dietary supplements, behavioral therapy, physical therapy etc., or any planned change of medications, supplements, or therapies during the study * have a current diagnoses of cachexia * planning on becoming pregnant, currently pregnant or lactating
a study of a new type of insulin in participants with type 2 diabetes on insulin injection therapy

Conditions: Diabetes Mellitus, Type 2

Summary: the study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes a test formulation of insulin lispro and the effect of the test formulation on blood sugar levels. side effects and tolerability will be documented. the study will be conducted in two parts (part a and part b) to achieve its objectives. participants are expected to enroll in both parts.


Eligibility criteria:
inclusion criteria: * are male or female participants with type 2 diabetes mellitus (t2dm) * are on stable prandial insulin as a multiple daily injection regimen, plus/minus basal insulin, with or without a stable dose of metformin, for at least 3 months before screening * have a body mass index (bmi) no greater than 35.0 kilogram per square meter (kg/m²) * have blood pressure, pulse rate, electrocardiogram (ecg), blood and urine laboratory test results acceptable for the study * have had no episodes of severe hypoglycemia in the past 6 months (requiring assistance in treatment by a second party) * have venous access sufficient to allow for blood sampling * have provided written consent and are willing to follow study procedures and commit to the study duration exclusion criteria: * are currently enrolled, or have participated within the last 30 days, in a clinical trial or any other type of medical research judged to be incompatible with this study * have previously completed or withdrawn from this study * have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate in the study * had blood loss of more than 500 milliliters (ml) within the last month * are treated with a continuous subcutaneous insulin infusion (insulin pump)
individualized comprehensive atherosclerosis risk-reduction evaluation program

Conditions: Atherosclerosis

Summary: this study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. this will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) standard management group (diagnosed and/or treated according to standard of care) and 2) individualized management group (standard of care plus genetic testing and coronary artery calcium scans).

the purpose of this proposal is to create a large, community-based demonstration project to evaluate the value of a highly individualized approach to atherosclerosis risk reduction. in this project we set out to compare the delivery of appropriate therapies and resource utilization using current national guidelines for the management of atherosclerosis and will compare this to using a highly individualized approach for atherosclerosis risk reduction, based on the evaluation of specific features in individuals and tailoring management based on this evaluation. we plan to show that utilizing the icare program, more patients will receive appropriate diagnoses and subsequent therapies in a more efficient manner.

Eligibility criteria:
inclusion criteria: * no known coronary artery disease * no prior coronary disease by cardiac catheterization (≤39% in any major epicardial vessel) * no prior myocardial infarction * no prior st-elevation myocardial infarction (1 mm st-elevation in 2 contiguous leads) * no prior non-st-elevation myocardial infarction (ck-mb \> 2x uln or elevated troponin that is indicative of myocardial necrosis based on local institutional cutpoints) * no prior coronary revascularization procedure * intermediate or high framingham risk score (10-year risk 10% or greater) * ability and willingness to provide consent and authorization for use of phi exclusion criteria: * presence of known cardiomyopathy * presence of permanent pacemaker, defibrillator, or crt device * presence of clinically significant, uncontrolled arrhythmia (chronic or paroxysmal atrial fibrillation is not an exclusion. arrhythmias treated successfully with ablation are not an exclusion. * presence of a known genetic abnormality of cholesterol metabolism (e.g. familial hypercholesterolemia) * inability or unwillingness to adhere to follow up schedule * inability or unwillingness to provide informed consent and authorization for use of phi

Keywords: atherosclerosis
the kunshan elderly health study

Conditions: Cardiovascular Diseases; Diabetes Mellitus; Cancer; Cognitive Impairment; Sarcopenia; Frailty; Depression

Summary: the kunshan elderly health study (kehs) is a community-based prospective cohort study of chronic disease, mortality and associated factors among elderly adults in kunshan, eastern china.

the kunshan elderly health study (kehs) is a project organized by the soochow university, in collaboration with the kunshan \& suzhou centers for disease control and prevention. it was primarily designed to assess risk factors (nutritional, metabolic, lifestyle, etc.) for chronic diseases and mortality among community residents aged 65 years and above, and explore effective intervention measures, so as to ultimately reduce the burden of disease and promote healthy aging. in addition, findings of this study would contribute to further understanding of pathogenesis of the chronic diseases and provide new ideas for precise prevention, drug development and risk prediction.

Eligibility criteria:
inclusion criteria: * locally registered-residents in kunshan * aged 65 years or above * voluntary agreement to participate in the study (with written informed consent) exclusion criteria: * patients with stroke, coronary heart disease or cancer * patients with severe physical or mental illness * people unable to complete the survey

Keywords: nutrition lifestyle cohort elderly